Metronomic oral cyclophosphamide (MOC) therapy in the recurrent and advanced ovarian cancer patients: a retrospective study
Journal Title: IP International Journal of Medical Paediatrics and Oncology - Year 2017, Vol 3, Issue 2
Abstract
Introduction: To evaluate the efficacy of cycled oral cyclophosphamide therapy in recurrent and advanced ovarian cancer patients. Materials and Method: Recurrent and advanced ovarian cancer patients who are unfit for intensive chemotherapy were prescribed oral cyclophosphamide at the dose of 50 mg twice daily for 10 days, cycled every 28 days. Treatment-related toxicity was[N1] assessed by National cancer institute – common terminology criteria for adverse events(NCI-CTCAE) and response to treatment were assessed by Response evaluation criteria in solid tumours (RECIST) and clinical assessment. Progression-free (PFS), and overall survival (OS) were assessed using Kaplan meier survival analysis. Results: 71 patients of ovarian cancer admitted to our centre from January 2012 to March 2015 with mean age of 61.2±0.74 years were analyzed: 44 patients (61.9%) were platinum refractory/resistant, while 26 patients (36.6%) were platinum sensitive; 60 patients (84%) had received atleast one previous chemotherapy before starting MOC. The objective response rate (ORR) (complete and partial response) was 20%. Stable disease was seen in 22 patients (30.9%) and 17patients had response duration ≥6 months, 8 patients had continued response for more than 1 year. Progression during treatment was observed in 49 patients (69.01%). Median PFS was 5 months (range 2 – 25 months), and the 12-month PFS was 11%; and the 12-month OS was 26% Median PFS for patients who responded to MOC was 9 months whereas 2 months for those who progressed (p = 0.01). Median OS of responding patients was 14 months whereas it was 8 months for patients progressive on MOC (p = 0.02). No significant toxicity was observed. Conclusions: MOC is an effective therapy in the treatment of recurrent and advanced ovarian cancer patients, unfit for intensive chemotherapy.
Authors and Affiliations
V. Arun Ramanan, K. Kalaichelvi, S. Lakshminarasimhan
Keywords
Related Articles
- EP ID EP300713
- DOI 10.18231/2455-6793.2017.0013
- Views 101
- Downloads 0
Knowledge on infant and young feeding in first time mothers with babies aged less than one month attending out-patient department at a tertiary care rural hospital
Aim: To assess the knowledge on infant and young child feeding (till 2years of age) in first time mothers with babies aged less than one month attending paediatric outpatient department (OPD). Design: Descriptive study R...
Evaluation of short stature in paediatric age group in rural medical college
Introduction Short stature is defined as height below 3rd centile or less than two standard deviations SDs below the median height for that age and sex according to the population standard Approximately 3 children in any...
Current practice and emerging trends in management of common surgical congenital malformations in neonates
Congenital malformations are significant but underrecognized cause of mortality and morbidity due to disability in neonates in almost every part of the world. Their occurrence, subsequent management and outcome are direc...
Prevalence and causation of anemia among pediatric age group patients
Background: Anemia prevalence in all age group children continues to remain in most parts of India and Asia. One of the most common factors in causation of anaemia is malnutrition; iron deficiency making the most of it....
Comparative study of analgesic effect of breast feeding versus dextrose during heel lance in neonates
Aim: Firstly, to assess the level of pain in new-borns enrolled in the study, after heel lance. Secondly, to determine the effect of oral dextrose solution and breast feeding on procedural pain in new-borns in the experi...